The Pneumology Service of the Consorci Sanitari Integral acts as a point of reference for the adult population of the Baix Llobregat Center and Hospitalet Nord, providing specialized attention to pathologies of the respiratory system, with a care model centered on the person.
Presentation The Pneumology Service of the Integral Health Consortium acts as a point of reference for the adult population of the Baix Llobregat Center and Hospitalet Nord, providing specialized attention to pathologies of the respiratory system, with a care model centered on the person. This ranges from acute processes that require hospitalization to care for chronicity, through the ambulatory study of complex processes that require highly specialized treatments (biological drugs, home respiratory therapy devices...)
Throughout this process, we work in collaboration with the different healthcare facilities in our area
The Pneumology Service has monographic consultations and/or Day Hospital for the care of the most complex patients. However, the need for a multidisciplinary approach has led to the creation of working groups in which the Pneumologists work together with other professionals from the Consortium, Primary Care and/or the Bellvitge University Hospital
Specialized ambulatory care is provided by Pneumologists from the Service who visit the Specialized Care Centers (CAE) in Ronda la Torrassa, Cornellà de Llobregat and Sant Feliu de Llobregat. In these centers, visits derived from Primary Care are made to solve the most prevalent respiratory pathologies or the patient is referred to the most convenient device depending on the basic pathology. Collaboration with A. Primary through regular meetings (face-to-face or online) and virtual consultation.
Update date: 11/05/2023
In this section appear the professionals of the Integral Health Consortium who have authorized the display of their personal data.
Update date: 11/05/2023
Patients who require diagnosis and/or inpatient treatment for acute respiratory pathology or for exacerbation of a chronic respiratory process (with or without respiratory insufficiency). Includes 6 beds with monitoring for observation of patients in serious condition and application of non-invasive respiratory support therapies.
|
Update date: 11/05/2023
Lung disease related to tobacco consumption. It is a chronic and progressive disease. Approximately 25% of smokers will develop COPD. Its onset is insidious with non-specific symptoms such as cough, expectoration and acute bronchitis which are given little importance. This means that it takes time to diagnose it and it is usually done in phases when the respiratory capacity is already significantly affected. Its main symptom is dyspnea (shortness of breath) on exertion. The only action that stops the progress of the disease is to stop smoking. The main treatment is inhaled bronchodilator drugs, which improve symptoms. When the pulmonary function is very impaired, respiratory failure may appear and treatment with oxygen at home must be instituted. It is often associated with other diseases (comorbidities).
of a cardiovascular nature (often linked to the same risk factor, tobacco), but also a consequence of the decrease in physical activity due to suffocation (obesity, loss of muscle strength, osteoporosis) and affectation of the psychosocial sphere ( depression, anxiety, social isolation). In the advanced stages they usually require urgent care/admission and follow-up visits. All together conditions great burdens on the family environment. The millet approach is preventive with the promotion of healthy lifestyle habits.
Chronic inflammatory disease of the respiratory tract, conditioned in part by genetic factors, which causes narrowing of the bronchi in response to various stimuli (allergy, pollution, viral infections and some drugs such as anti-inflammatory drugs). The prevalence varies depending on age, sex and geographic location. The treatment is preferably with anti-inflammatory drugs and inhaled bronchodilators with the aim of maintaining control of the disease (symptoms and lung function) as well as preventing exacerbations, which can put the patient's life at risk
Adherence to treatment is key to achieving control. Patients who do the treatment at high doses and do not succeed
Controlling the disease should be evaluated at a specialist consultation
It is the first cause of death from cancer and its frequency is increasing in both men and women.
Largely related to tobacco. It is caused by disordered growth of the cells of the bronchial mucosa.
It is the second most common cancer in men and the fourth in women. It is the cancer with the highest mortality rate, but with the therapeutic advances of recent years, it is expected to be chronic. The best approach, however, is still to quit smoking and have healthy lifestyle habits.
Heterogeneous group of chronic diseases that are characterized by being infrequent,
difficult to diagnose and often require complex treatments. In all these diseases, the lung tissue is damaged (with or without a known cause) and does not heal well, with scars appearing that gradually replace the healthy tissue. As a result, there is a loss of lung function. According to the cause they can be classified into:
The symptoms are irritative cough and suffocation on exertion. In the forms associated with other diseases we will also find the
symptoms specific to these (arthritis, skin lesions...).
It is a disorder in which breathing is interrupted in whole or in part repeatedly during sleep. It affects 2-5% of the general population and is more common in men. Often associated with obesity.
Its consequences derive from:
It is proven that SAHS is an independent risk factor for the occurrence of cardiovascular disease (mainly hypertension, stroke, arrhythmia and heart failure. It is also associated with a greater risk of suffering traffic accidents)
Update date: 11/05/2023
The service participates in multicentre studies in the areas of tuberculosis, pulmonary fibrosis, tobacco, bronchiectasis, asthma and chronic obstructive pulmonary disease (COPD).
Update date: 11/05/2023
Update date: 11/05/2023
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-advertisement | 1 year | Set by the GDPR cookie consent plugin, this cookie is used to record the user's consent to cookies in the "Ad" category. |
cookielawinfo checkbox analytics | 1 year | Set by the GDPR cookie consent plugin, this cookie is used to record the user's consent to cookies in the "Analytics" category. |
cookielawinfo checkbox functional | 1 year | The cookie is set by the GDPR cookie consent plugin to record the user's consent to cookies in the "Functional" category. |
cookielawinfo-checkbox-Necessary | 1 year | Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Necessary" category . |
cookielawinfo-checkbox-fastrs | 1 year | Set by the GDPR cookie consent add-on, this cookie is used to store the user's consent to cookies in the "Other" category. |
cookielawinfo checkbox performance | 1 year | Set by the GDPR cookie consent add-on, this cookie is used to store the user's consent for cookies in the "Performance" category. |
CookieLawInfoConsent | 1 year | Record the default button state of the corresponding category & the CCPA state. It only works in coordination with the main cookie. |
Cookie | Duration | Description |
---|---|---|
__sharethis_cookie_test__ | Session | ShareThis sets this cookie to track which pages are being shared and by whom. |
Cookie | Duration | Description |
---|---|---|
_ga | 2 years | The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also tracks site usage for the site analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors. |
_ga_5515H28R8E | 2 years | This cookie is installed by Google Analytics. |